Acta Med Port 2017 Aug 31;30(7-8):534-540. Epub 2017 Aug 31.
Serviço de Doenças Infeciosas. Centro Hospitalar e Universitário de Coimbra. Coimbra. Portugal.
Download full-text PDF
J Travel Med 2009 Sep-Oct;16(5):344-8
Preventive Medicine and Epidemiology Department, Hospital Clinic/IDIBAPS, Barcelona, Spain.
Background: In recent years, the number of travelers aged >40 years who acquire hepatitis A while traveling has increased. Therefore, there is a need to review hepatitis A vaccination protocols in travelers. The aims of the study were to assess immunity levels to hepatitis A virus (HAV) in international travelers >40 years and to determine the least costly immunization strategy. Read More
Acta Med Port 2004 May-Jun;17(3):219-24. Epub 2004 Jun 30.
Serviço de Pediatria, Hospital de São Marcos, Braga.
The prevalence of the hepatitis A virus in a population determines the degree of morbidity associated with this illness, that is, the higher the morbidity, the lower the prevalence. This study aims to obtain the prevalence of total antibody to the hepatitis A virus in children, 5 and 8 years of age, and in adolescents, 14 years of age. The study was based on two samples: the serum of 64 healthy five-year-olds and 76 healthy eight-year-olds living in the proximity of the São Marcos Hospital in Braga and the serum of 311 adolescents, aged 14, from a total population of 536 adolescents attending schools in Braga, North of Portugal. Read More
J Travel Med 2006 Jul-Aug;13(4):212-8
Tufts University School of Medicine, Department of Medicine, Boston, MA, USA.
Immigrants to the United States from developing countries have a higher probability of previous infection with hepatitis A virus (HAV) and/or hepatitis B virus in their countries of origin. Prior knowledge of hepatitis A and B seroprevalence in this population may aid in determining the need for pretravel immunizations when these individuals travel to endemic regions. We conducted a retrospective analysis of hepatitis A and B serologies in a travel clinic population (from March 1999 through September 2002) to determine the seroprevalence in our predominantly highly educated foreign-born subjects. Read More
Travel Med Infect Dis 2014 Nov-Dec;12(6 Pt B):707-12. Epub 2014 Jul 17.
Institut Pasteur, Centre Médical, 209 rue de Vaugirard, 75015 Paris, France. Electronic address:
Background: Non-immune travelers are at risk of acquiring hepatitis B (HB) in high prevalence countries.
Method: At the Institut Pasteur Vaccination Center in a retrospective study we retrieved hepatitis B serological data from the vaccination database between 2008 and 2012. Serology (HBsAg, HBsAb and HBcAb) is proposed to travelers who have no information about their previous HB vaccination status if they travel to countries of high or intermediate prevalence of HB, for long or frequent trips. Read More